| Literature DB >> 7719933 |
R E Sobol1, H Fakhrai, D Shawler, R Gjerset, O Dorigo, C Carson, T Khaleghi, J Koziol, T A Shiftan, I Royston.
Abstract
A patient with glioblastoma multiforme (GBM) who had failed conventional therapy was treated with IL-2 gene therapy. The patient received 10 subcutaneous immunizations with autologous tumor cells and fibroblasts genetically modified to secrete IL-2 by retroviral gene transfer. An antitumor immune response mediated in part by CD8+ cytotoxic T cells was demonstrated with the patient's peripheral blood mononuclear cells. A magnetic resonance imaging (MRI) scan performed 4 weeks after the highest treatment dose revealed marked tumor necrosis. These results support the evaluation of this form of IL-2 gene therapy in additional patients with glioblastoma.Entities:
Mesh：
Substances：
Year: 1995 PMID： 7719933
Source DB: PubMed Journal: Gene Ther ISSN： 0969-7128 Impact factor: 5.250